NDASUBCUTANEOUSEMULSION
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAMCEVI ETM is a subcutaneous leuprolide mesylate emulsion approved by the FDA on August 25, 2025. Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist used primarily in advanced prostate cancer and endometriosis management. This formulation represents a novel delivery approach for an established mechanism of action.
Launch2.2 years to LOE
Early-stage product launch with moderate competitive pressure (30%) suggests active market entry phase requiring robust commercial infrastructure and field team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Started Jun 2023
93 enrolled
Puberty; Precocious, Central
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Started Sep 2017
144 enrolled
Prostatic Neoplasms
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
Started Aug 2014
137 enrolled
Prostatic Neoplasms
Career Relevance
CAMCEVI ETM launch roles (0 currently linked jobs) will emerge rapidly as commercial execution ramps at Accord Biopharma. Professionals joining this team should expect high-velocity market entry activities compressed into a 2.2-year exclusivity window, with emphasis on rapid adoption and competitive differentiation.
Worked on CAMCEVI ETM at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.